Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Mantle Cell Lymphoma Resource Center

News
Real-World Outcomes of Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory Mantle Cell Lymphoma With High-Risk Features
02/14/2024

Grace Taylor

Grace Taylor
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated...
02/14/2024
Journal of Clinical Pathways
Eliza A Hawkes, MD
Videos
Promising Advances in the Mantle Cell Lymphoma Treatment Landscape
02/13/2024

Featuring Eliza A Hawkes, MD

Featuring Eliza A Hawkes, MD
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some...
02/13/2024
Oncology
From Oncology
Bijal Shah, MD
Conference Coverage
Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape
01/08/2024

Featuring Bijal D. Shah, MD

Featuring Bijal D. Shah, MD
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the...
01/08/2024
Oncology
From Oncology
Mengyang Di, MD, PhD
Videos
Real-World BTK Inhibitor Utilization and Outcomes Following Discontinuation in Older Patients With MCL
12/14/2022
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed...
12/14/2022
Journal of Clinical Pathways
Conference Coverage
Bendamustine-Rituximab Followed by Rituximab ± Lenalidomide for Mantle Cell Lymphoma
12/10/2022

Katie Herman 

Katie Herman 
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and...
12/10/2022
Journal of Clinical Pathways
Tycel Phillips, MD
Videos
Frontline Therapies for Patients With Untreated and Relapsed Mantle Cell Lymphoma
09/14/2022
Tycel Phillips, MD, reviews standard therapies utilized for patients with mantle cell lymphoma, including nonaggressive regimens and BTK inhibitor therapies.
Tycel Phillips, MD, reviews standard therapies utilized for patients with mantle cell lymphoma, including nonaggressive regimens and BTK inhibitor therapies.
Tycel Phillips, MD, reviews...
09/14/2022
Journal of Clinical Pathways
News
Study Indicates Late Effects in Mantle Cell Lymphoma Treatment With or Without Transplantation Have Minimal Impact
09/12/2022

Yvette C Terrie

Yvette C Terrie
Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...
Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...
Results from a recent study...
09/12/2022
Journal of Clinical Pathways
News
Exploring Radiation Therapy for Orbital Involvement in Patients with Mantle Cell Lymphoma
09/12/2022

Yvette C Terrie

Yvette C Terrie
Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.
Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.
Mantle cell lymphoma with optic...
09/12/2022
Journal of Clinical Pathways
News
Exploring PD-1/PD-L1 Expression in Mantle Cell Lymphoma and its Significance as an Immune Check Point Inhibitor
08/26/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recent study suggest that neither PD-1 nor its ligands represent relevant targets for mantle cell lymphoma treatment, however, age may impact the efficiency of immune checkpoint inhibitors.
Findings from a recent study suggest that neither PD-1 nor its ligands represent relevant targets for mantle cell lymphoma treatment, however, age may impact the efficiency of immune checkpoint inhibitors.
Findings from a recent study...
08/26/2022
Journal of Clinical Pathways
News
Autologous Stem-Cell Transplant Underutilized Among Patients With Mantle Cell Lymphoma in US Community Settings
08/16/2022

Yvette C Terrie

Yvette C Terrie
Study findings reveal that among a large cohort of patients treated primarily in the US community setting, one in four patients received cytarabine or autologous stem-cell transplant consolidation, indicating the need to develop treatments...
Study findings reveal that among a large cohort of patients treated primarily in the US community setting, one in four patients received cytarabine or autologous stem-cell transplant consolidation, indicating the need to develop treatments...
Study findings reveal that among...
08/16/2022
Journal of Clinical Pathways
News
Survey Explores Prescriber Perceptions and Preferences Regarding First Line Therapy for MCL
07/27/2022

Ellen Kurek

Ellen Kurek
A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.
A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.
A survey evaluated first-line...
07/27/2022
Journal of Clinical Pathways

Expert Insights

Eliza A Hawkes, MD
Videos
Promising Advances in the Mantle Cell Lymphoma Treatment Landscape
02/13/2024

Featuring Eliza A Hawkes, MD

Featuring Eliza A Hawkes, MD
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some...
02/13/2024
Oncology
Bijal Shah, MD
Conference Coverage
Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape
01/08/2024

Featuring Bijal D. Shah, MD

Featuring Bijal D. Shah, MD
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the...
01/08/2024
Oncology
Mengyang Di, MD, PhD
Videos
Real-World BTK Inhibitor Utilization and Outcomes Following Discontinuation in Older Patients With MCL
12/14/2022
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed...
12/14/2022
Journal of Clinical Pathways
Tycel Phillips, MD
Videos
Frontline Therapies for Patients With Untreated and Relapsed Mantle Cell Lymphoma
09/14/2022
Tycel Phillips, MD, reviews standard therapies utilized for patients with mantle cell lymphoma, including nonaggressive regimens and BTK inhibitor therapies.
Tycel Phillips, MD, reviews standard therapies utilized for patients with mantle cell lymphoma, including nonaggressive regimens and BTK inhibitor therapies.
Tycel Phillips, MD, reviews...
09/14/2022
Journal of Clinical Pathways
Mayur Narkhede, MD
Videos
Real-World Treatment Patterns and Outcomes Among Patients With Mantle Cell Lymphoma
07/21/2022
Mayur Narkhede, MD, analyzed treatment patterns among patients with mantle cell lymphoma at different lines of therapy, focusing on BTKi use, and compared outcomes with known prognostic factors.
Mayur Narkhede, MD, analyzed treatment patterns among patients with mantle cell lymphoma at different lines of therapy, focusing on BTKi use, and compared outcomes with known prognostic factors.
Mayur Narkhede, MD, analyzed...
07/21/2022
Journal of Clinical Pathways
Real-World Practice Patterns and Predictors of Survival in Older Patients With MCL
ENGAGING EXPERTS
Real-World Practice Patterns and Predictors of Survival in Older Patients With MCL
01/15/2021
David Bond, MD, discusses results from a real-world study highlighting risk factors, clinical outcomes, andpredictors of survival in older patients with MCL treated in the rituximab era.
David Bond, MD, discusses results from a real-world study highlighting risk factors, clinical outcomes, andpredictors of survival in older patients with MCL treated in the rituximab era.
David Bond, MD, discusses...
01/15/2021
Journal of Clinical Pathways
Novel BTK Inhibitor Promising for Mantle Cell Lymphoma
ENGAGING EXPERTS
Novel BTK Inhibitor Promising for Mantle Cell Lymphoma
06/23/2020
Peter Martin, MD, Weill Cornell Medicine, New York, New York, discusses the data that led to the recent accelerated approval of zanubrutinib for the treatment of patients with mantle cell lymphoma.
Peter Martin, MD, Weill Cornell Medicine, New York, New York, discusses the data that led to the recent accelerated approval of zanubrutinib for the treatment of patients with mantle cell lymphoma.
Peter Martin, MD, Weill Cornell...
06/23/2020
Journal of Clinical Pathways
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
Blog
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
08/07/2024
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together...
08/07/2024
Journal of Clinical Pathways
Farrukh Awan, MD
Videos
Chronic Lymphocytic Leukemia Treatment Updates
07/31/2024
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some...
07/31/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Why People Should Care About How Health Care Works (Part 1)
07/29/2024
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part...
07/29/2024
Cancer Care Business Exchange
Ivy Altomare, MD
Videos
Characteristics of Clinical Trials in Community Oncology Practices Across the US
07/23/2024
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an...
07/23/2024
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Sandip Patel, MD
Videos
Recent Advancements in the Non–Small Cell Lung Cancer Treatment Landscape
07/22/2024
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the...
07/22/2024
Journal of Clinical Pathways
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Show Me the Medical Evidence
07/15/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health...
07/15/2024
Cancer Care Business Exchange
Gunjan Sharma
Interview
Leveraging Data to Enhance Patient Care: Addressing Social Determinants of Health in Oncology Care
07/10/2024
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst...
07/10/2024
Journal of Clinical Pathways
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways

Newsfeed

News
Real-World Outcomes of Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory Mantle Cell Lymphoma With High-Risk Features
02/14/2024

Grace Taylor

Grace Taylor
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated...
02/14/2024
Journal of Clinical Pathways
Bijal Shah, MD
Conference Coverage
Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape
01/08/2024

Featuring Bijal D. Shah, MD

Featuring Bijal D. Shah, MD
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the...
01/08/2024
Oncology
Conference Coverage
Bendamustine-Rituximab Followed by Rituximab ± Lenalidomide for Mantle Cell Lymphoma
12/10/2022

Katie Herman 

Katie Herman 
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and...
12/10/2022
Journal of Clinical Pathways
News
Study Indicates Late Effects in Mantle Cell Lymphoma Treatment With or Without Transplantation Have Minimal Impact
09/12/2022

Yvette C Terrie

Yvette C Terrie
Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...
Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...
Results from a recent study...
09/12/2022
Journal of Clinical Pathways
News
Exploring Radiation Therapy for Orbital Involvement in Patients with Mantle Cell Lymphoma
09/12/2022

Yvette C Terrie

Yvette C Terrie
Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.
Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.
Mantle cell lymphoma with optic...
09/12/2022
Journal of Clinical Pathways
News
Exploring PD-1/PD-L1 Expression in Mantle Cell Lymphoma and its Significance as an Immune Check Point Inhibitor
08/26/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recent study suggest that neither PD-1 nor its ligands represent relevant targets for mantle cell lymphoma treatment, however, age may impact the efficiency of immune checkpoint inhibitors.
Findings from a recent study suggest that neither PD-1 nor its ligands represent relevant targets for mantle cell lymphoma treatment, however, age may impact the efficiency of immune checkpoint inhibitors.
Findings from a recent study...
08/26/2022
Journal of Clinical Pathways
News
Autologous Stem-Cell Transplant Underutilized Among Patients With Mantle Cell Lymphoma in US Community Settings
08/16/2022

Yvette C Terrie

Yvette C Terrie
Study findings reveal that among a large cohort of patients treated primarily in the US community setting, one in four patients received cytarabine or autologous stem-cell transplant consolidation, indicating the need to develop treatments...
Study findings reveal that among a large cohort of patients treated primarily in the US community setting, one in four patients received cytarabine or autologous stem-cell transplant consolidation, indicating the need to develop treatments...
Study findings reveal that among...
08/16/2022
Journal of Clinical Pathways
News
Survey Explores Prescriber Perceptions and Preferences Regarding First Line Therapy for MCL
07/27/2022

Ellen Kurek

Ellen Kurek
A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.
A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.
A survey evaluated first-line...
07/27/2022
Journal of Clinical Pathways
News
Evaluating Attrition Rates and Treatment Outcomes Among Patients With MCL
07/14/2022

Ellen Kurek

Ellen Kurek
Findings from a recent real-world analysis on patients with mantle cell lymphoma revealed high attrition rates, as well as a need for more effective treatment options for those in earlier lines of therapy.
Findings from a recent real-world analysis on patients with mantle cell lymphoma revealed high attrition rates, as well as a need for more effective treatment options for those in earlier lines of therapy.
Findings from a recent...
07/14/2022
Journal of Clinical Pathways
Conference Coverage
Treatment Patterns and Efficacy of Bruton Tyrosine Kinase Inhibitors in Patients With MCL
06/09/2022

Robert Fee

Robert Fee
Retrospective multicenter chart review conducted in the Cardinal Health Oncology Provider Extended Network assessed treatment patterns and associated outcomes in patients with MCL who were treated with BTKi.
Retrospective multicenter chart review conducted in the Cardinal Health Oncology Provider Extended Network assessed treatment patterns and associated outcomes in patients with MCL who were treated with BTKi.
Retrospective multicenter chart...
06/09/2022
Journal of Clinical Pathways
News
Examining Treatment Delay Trends in Patients With Lung Cancer
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways
News
Improving Care for Patients With Cancer Through Early Goal of Care Discussions
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology

Interactive Features

Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Survival Outcomes in Patients With MCL Treated With Bruton Tyrosine Kinase Inhibitors
04/12/2022
True or False: BTK inhibitors in the second-line setting improve overall survival and lymphoma-specific survival among patients with MCL.
True or False: BTK inhibitors in the second-line setting improve overall survival and lymphoma-specific survival among patients with MCL.
True or False: BTK inhibitors in...
04/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Treatment Patterns for MCL
01/20/2022
True or False: Bendamustine plus rituximab is the most commonly used first-line treatment for MCL in the US, while receipt of stem cell transplant is uncommon.
True or False: Bendamustine plus rituximab is the most commonly used first-line treatment for MCL in the US, while receipt of stem cell transplant is uncommon.
True or False: Bendamustine plus...
01/20/2022
Journal of Clinical Pathways
Quiz
Quiz: Rituximab Among Older Patients With MCL
09/03/2021
True or False: Older patients with MCL may not benefit from maintenance rituximab, due to an inability to tolerate this treatment.
True or False: Older patients with MCL may not benefit from maintenance rituximab, due to an inability to tolerate this treatment.
True or False: Older patients...
09/03/2021
Journal of Clinical Pathways
Quiz
Quiz: Impact of Comorbidities on Treatment Choices for Older Patients With MCL
04/28/2021
04/28/2021
Journal of Clinical Pathways
Quiz
Quiz: Is KTE-X19 a Cost-Effective Treatment for MCL?
04/23/2021
04/23/2021
Journal of Clinical Pathways
Quiz
Quiz: MRD Status for Patients With MCL
03/08/2021
03/08/2021
Journal of Clinical Pathways
Quiz
Quiz: Is Pre-Transplant MRD Status Predictive of Survival in MCL?
02/16/2021
02/16/2021
Journal of Clinical Pathways
Quiz
Quiz: Economic Burden of MCL in the VHA Population
09/29/2020
09/29/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Recent Stories

News
Real-World Outcomes of Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory Mantle Cell Lymphoma With High-Risk Features
02/14/2024

Grace Taylor

Grace Taylor
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated...
02/14/2024
Journal of Clinical Pathways
Eliza A Hawkes, MD
Videos
Promising Advances in the Mantle Cell Lymphoma Treatment Landscape
02/13/2024

Featuring Eliza A Hawkes, MD

Featuring Eliza A Hawkes, MD
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some...
02/13/2024
Oncology
Bijal Shah, MD
Conference Coverage
Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape
01/08/2024

Featuring Bijal D. Shah, MD

Featuring Bijal D. Shah, MD
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the...
01/08/2024
Oncology
Mengyang Di, MD, PhD
Videos
Real-World BTK Inhibitor Utilization and Outcomes Following Discontinuation in Older Patients With MCL
12/14/2022
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed...
12/14/2022
Journal of Clinical Pathways
Conference Coverage
Bendamustine-Rituximab Followed by Rituximab ± Lenalidomide for Mantle Cell Lymphoma
12/10/2022

Katie Herman 

Katie Herman 
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and...
12/10/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement